A U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices.

The U.S. Patent and Trademark Office’s review board ruled against Mr. Bass’s challenge of two patents on Acorda Therapeutics Inc.’s multiple sclerosis drug Ampyra. In...